S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
Top-Rated Stocks  
NASDAQ:AXSM

Axsome Therapeutics - AXSM Stock Forecast, Price & News

$77.29
+0.39 (+0.51%)
(As of 12/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$75.18
▼
$80.87
50-Day Range
$39.94
▼
$76.90
52-Week Range
$20.63
▼
$80.87
Volume
2.36 million shs
Average Volume
1.34 million shs
Market Capitalization
$3.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$111.55

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
44.3% Upside
$111.55 Price Target
Short Interest
Bearish
19.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.33mentions of Axsome Therapeutics in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.42) to ($3.40) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

114th out of 1,033 stocks

Pharmaceutical Preparations Industry

42nd out of 502 stocks

See Top Rated MarketRank™ Stocks Here
AXSM stock logo

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock News Headlines

November 30, 2022 | marketbeat.com
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.
December 5, 2022 | americanbankingnews.com
Brokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Price Target at $111.55
December 3, 2022 | americanbankingnews.com
FY2022 EPS Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM) Reduced by Cantor Fitzgerald
December 2, 2022 | finance.yahoo.com
Axsome Therapeutics Stock: Bear vs. Bull
December 2, 2022 | americanbankingnews.com
Axsome Therapeutics (NASDAQ:AXSM) PT Raised to $86.00
December 1, 2022 | americanbankingnews.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Increased to $85.00 by Analysts at SVB Leerink
November 30, 2022 | msn.com
Axsome Therapeutics's Return On Capital Employed Insights
November 30, 2022 | americanbankingnews.com
Axsome Therapeutics (NASDAQ:AXSM) Stock Rating Reaffirmed by Mizuho
November 28, 2022 | msn.com
$1000 Invested In This Stock 5 Years Ago Would Be Worth $13,000 Today
November 28, 2022 | marketwatch.com
Axsome Therapeutics Shares Hit 52-Week High, Propelled by Alzheimer's Study >AXSM
November 28, 2022 | msn.com
Axsome Therapeutics Unusual Options Activity
November 28, 2022 | benzinga.com
Thinking about trading options or stock in Axsome Therapeutics, Sarepta Therapeutics, Las Vegas Sands, Apple, or Microsoft?
November 28, 2022 | marketwatch.com
Axsome Shares Rally Premarket on Alzheimer's Agitation Study Success >AXSM
November 28, 2022 | seekingalpha.com
Axsome says candidate for Alzheimer’s agitation met main goal in late-stage trial
November 28, 2022 | finance.yahoo.com
3 Growth Stocks to Buy That Could Skyrocket
November 28, 2022 | finance.yahoo.com
Want to Double Your Money? Buying These Stocks Could be a Genius Move
November 28, 2022 | finance.yahoo.com
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
November 28, 2022 | finance.yahoo.com
Axsome Therapeutics Investigational Drug Lowers Risk Of Agitation Relapse In Alzheimer's Patients
November 24, 2022 | finance.yahoo.com
Prediction: This Growth Stock Could Double in 2023
November 24, 2022 | seekingalpha.com
Axsome: Strong Earnings Signal More Upside
November 23, 2022 | finance.yahoo.com
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 20, 2022 | finance.yahoo.com
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
November 11, 2022 | finance.yahoo.com
Is Axsome Therapeutics Stock a Buy Now?
November 11, 2022 | markets.businessinsider.com
SVB Securities Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
November 10, 2022 | finance.yahoo.com
Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its Third-Quarter Results
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Company Calendar

Last Earnings
11/08/2021
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
CUSIP
N/A
CIK
1579428
Web
axsome.com
Phone
(212) 332-3241
Fax
212-320-0245
Employees
108
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$111.55
High Stock Price Forecast
$210.00
Low Stock Price Forecast
$80.00
Forecasted Upside/Downside
+44.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-130,400,000.00
Net Margins
N/A
Pretax Margin
-622.89%
Return on Equity
-312.00%
Return on Assets
-90.97%

Debt

Debt-to-Equity Ratio
0.60
Current Ratio
4.19
Quick Ratio
4.15

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.41 per share
Price / Book
188.51

Miscellaneous

Outstanding Shares
43,426,000
Free Float
32,135,000
Market Cap
$3.36 billion
Optionable
Optionable
Beta
1.86

Key Executives

  • Dr. Herriot Tabuteau M.D. (Age 54)
    Founder, Chairman, CEO & Pres
    Comp: $1.06M
  • Mr. Nick Pizzie CPAMr. Nick Pizzie CPA (Age 47)
    M.B.A., Chief Financial Officer
    Comp: $553.97k
  • Mr. Mark L. Jacobson (Age 39)
    COO & Sec.
    Comp: $554.72k
  • Mr. Hunter Murdock Esq.
    Exec. VP of Legal & Compliance
  • Dr. Amanda Jones Pharm.D. (Age 39)
    Sr. VP of Clinical Devel.
  • Ms. Lori Englebert M.B.A. (Age 44)
    Exec. VP of Commercial & Bus. Devel.
  • Mr. Kevin Laliberte Pharm.D. (Age 44)
    Exec. VP of Product Strategy
  • Joseph Debrah-Afful CPA
    M.B.A., Director of Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings or view top-rated stocks.

What is Axsome Therapeutics' stock price forecast for 2023?

10 brokers have issued 12 month target prices for Axsome Therapeutics' stock. Their AXSM share price forecasts range from $80.00 to $210.00. On average, they predict the company's share price to reach $111.55 in the next year. This suggests a possible upside of 45.1% from the stock's current price.
View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2022?

Axsome Therapeutics' stock was trading at $37.78 at the start of the year. Since then, AXSM shares have increased by 103.5% and is now trading at $76.90.
View the best growth stocks for 2022 here.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our AXSM earnings forecast.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.02. During the same quarter in the previous year, the firm posted ($0.58) earnings per share.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.17%), BlackRock Inc. (5.05%), RTW Investments LP (4.33%), PFM Health Sciences LP (3.82%), Citadel Advisors LLC (0.00%) and State Street Corp (1.64%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $76.90.

How much money does Axsome Therapeutics make?

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $3.34 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

The company employs 108 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 12/5/2022 by MarketBeat.com Staff